Asia-Pacific Prescription Digital Therapeutics (PDTx) Market, By Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults) – Industry Trends and Forecast to 2029
Market Analysis and Size
Prescription digital therapies are a unique strategy that allows software implementations to quickly treat major diseases. It is designed to deliver evidence-based treatment everywhere and at any time and give physicians real-time data on patient progress. Prescription digital therapeutics have been developed and are in the development stage for a variety of diseases, including substance use disorder (SUD), opioid use disorder (OUD), ADHD, major depressive disorder (MDD), insomnia, multiple sclerosis, oncology, migraine, epilepsy, autism spectrum disorder, and cardiovascular disease. Patients with various unmet requirements may find prescription digital therapies to be the most crucial aspect of their lives.
Data Bridge Market Research analyses that the Asia-Pacific prescription digital therapeutics (PDTx) market was valued at USD 96.38 million in 2021 and is expected to reach USD 545.70 million by 2029, registering a CAGR of 24.2% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Mechanism (Input Mechanisms, Output Mechanisms), Category (Medication Augmentation, Medication Replacement), Treatment (Outpatient Treatment, Monotherapy), Software (Software for Respiratory Conditions, Software for Mental Health, Software for Opioid Use Disorder, Software for Diabetes, Others), Services (Behavioral Microservices, Medical Microservices), App Accessibility (Android, iOS, Windows), App Type (Native Apps, Web Apps), Application (Substance Use Disorder (SUD), Opioid Use Disorder (OUD), Attention Deficit/Hyperactivity Disorder (ADHD), Alzheimer’s Disease, Major Depressive Disorder (MDD), Insomnia, Epilepsy, Movement Disorder, Multiple Sclerosis, Migraine, Autism Spectrum Disorder, Oncology, Inflammation, Respiratory, Cardiovascular, Pain Management, Metabolic Conditions, Others), Patients (Children, Adults),
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
ResMed (US), SAMSUNGHEALTHCARE (South Korea), Biofourmis (US), Novartis AG (Switzerland), Medtronic (Ireland), Pear Therapeutics, Inc. (US), Voluntis (France)
|
|
Market Opportunities
|
|
Market Definition
Prescription digital therapies is a type of software that is used to treat a variety of ailments. Prescription digital medicines were created by combining biology and technology. Artificial intelligence, diverse algorithms, and virtual reality are used to create these therapeutic instruments. Patients might use prescription digital therapeutics software and services to get any form of treatment whenever and wherever they needed it. Prescription digital treatments have gained a lot of popularity since they are tightly regulated by the FDA and other regulatory authorities and can only be used with a proper prescription from a doctor.
Asia-Pacific Prescription Digital Therapeutics (PDTx) Market Dynamics
Drivers
- Rise in the prevalence of chronic diseases
The surging prevalence of chronic diseases is a major factor driving the prescription digital therapeutics (PDTx) market's growth rate during the forecast period of 2022-2029. As per the World Health Organization (WHO), 463 million adults would have diabetes in 2020. According to predictions, there would be roughly 629 million diabetics worldwide by 2045.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of prescription digital therapeutics (PDTx) market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising adoption rate of smartphones and tablets will expand the prescription digital therapeutics (PDTx) market. Additionally, increasing government initiatives for better healthcare services and surging geriatric population will result in the expansion of prescription digital therapeutics (PDTx) market. Along with this, easy accessibility, patient comfort, and the potentiality to influence behavioural change will enhance the market's growth rate.
Opportunities
- Strong pipeline of potential products
A significant pipeline of potential items projected to be released throughout the forecast period will provide beneficial opportunities for the prescription digital therapeutics (PDTx) market growth. Pear-011 (anxiety GAD), Pear-015 (depression MDD), which are used in the treatment of adults with chronic insomnia and depression, and CT-152 (major depressive disorder), CT-155 (schizophrenia), which are used in the treatment of adults with schizophrenia and depression, are illustrations of potential pear therapeutics clinical therapeutics products in phase III. As a result, various late-stage drugs in the pipeline are anticipated to give attractive prospects for the digital therapeutics market to flourish.
The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the biologics market growth. Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of prescription digital therapeutics (PDTx) during the forecast period.
Restraints/Challenges
On the other hand, patient data privacy concerns will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the prescription digital therapeutics (PDTx) market. Additionally, strict government regulations and lack of awareness about digital therapeutics in developing countries will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This Asia-Pacific prescription digital therapeutics (PDTx) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific prescription digital therapeutics (PDTx) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Prescription digital therapeutics (PDTx) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Asia-Pacific Prescription Digital Therapeutics (PDTx) Market
COVID-19 has a positive general influence on the prescription digital therapeutics (PDTx) sector. Due to increased global awareness of the relevance of digital health, the prevalence of mental illness, and the rate of drug usage. Furthermore, because individuals were forced to stay at home during the pandemic, less physical exercise, an unhealthy lifestyle, and mental stress increased the prevalence of chronic diseases. As a result, demand for prescription digital therapeutics (PDTx) devices and software is increasing around the world. The industry is expected to increase further since regulatory clearances for prescription digital therapeutics (PDTx)-based treatments have recently been eased.
In the middle of the COVID-19 outbreak, the US FDA issued provisional advice for Pear Therapeutics' mental health medications. It also implies that regulatory agencies recognize the significance of digital therapeutics goods. In addition, digital health businesses in the United States raised USD 5.4 billion in venture capital in the first half of 2020, a record high in the history of digital health funding, indicating that investors believe these solutions are necessary. Hence, the COVID-19 pandemic is predicted to boost the market for prescription digital therapeutics (PDTx).
Asia-Pacific Prescription Digital Therapeutics (PDTx) Market Scope
The Asia-Pacific prescription digital therapeutics (PDTx) market is segmented on the basis of mechanism, category, treatment, software, services, app accessibility, app type, application and patients. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Mechanism
- Input Mechanisms
- Output Mechanisms
Category
- Medication Augmentation
- Medication Replacement
Treatment
- Outpatient Treatment
- Monotherapy
Software
- Software for Respiratory Conditions
- Software for Mental Health
- Software for Opioid Use Disorder
- Software for Diabetes
- Others
Services
- Behavioral Microservices
- Medical Microservices
App Accessibility
- Android
- iOS
- Windows
App Type
- Native Apps
- Web Apps
Application
- Substance Use Disorder (SUD)
- Opioid Use Disorder (OUD)
- Attention Deficit/Hyperactivity Disorder (ADHD)
- Alzheimer’s Disease
- Major Depressive Disorder (MDD)
- Insomnia
- Epilepsy
- Movement Disorder
- Multiple Sclerosis
- Migraine
- Autism Spectrum Disorder
- Oncology
- Inflammation
- Respiratory
- Cardiovascular
- Pain Management
- Metabolic Conditions
- Others
Patients
- Children
- Adults
Asia-Pacific Prescription Digital Therapeutics (PDTx) Market Regional Analysis/Insights
The Asia-Pacific prescription digital therapeutics (PDTx) market is analysed and market size insights and trends are provided by country, mechanism, category, treatment, software, services, app accessibility, app type, application and patients as referenced above.
The countries covered in the Asia-Pacific prescription digital therapeutics (PDTx) market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
Japan dominates the Asia-Pacific prescription digital therapeutics (PDTx) market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the rising healthcare expenditure and increasing prevalence of chronic diseases will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Prescription Digital Therapeutics (PDTx) Market Share Analysis
The Asia-Pacific prescription digital therapeutics (PDTx) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Asia-Pacific prescription digital therapeutics (PDTx) market.
Some of the major players operating in the Asia-Pacific prescription digital therapeutics (PDTx) market are:
- ResMed (US)
- SAMSUNGHEALTHCARE (South Korea)
- Biofourmis (US)
- Novartis AG (Switzerland)
- Medtronic (Ireland)
- Pear Therapeutics, Inc. (US)
- Voluntis (France)
SKU-